An Immune Model Incorporating NK Cells and IL-12 to Predict the Efficacy of the Initial Treatment Cycle of Efgartigimod in Generalized Myasthenia Gravis.

Drug Des Devel Ther · 2026 · PMC13197354 · PMID 42182584

Europe PMC DOI

hedged sentences

0.0950

closest p · 1.9× alpha

0.0950

boldest claim

The sentences

showed a trendp = 0.095so close (0.05 < p ≤ 0.1)

Non-responders had significantly higher baseline NK cell counts ( p = 0.013) and showed a trend toward lower IL-12p70 levels ( p = 0.095).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The prevalence of thymoma was numerically higher in the non-responder group compared to the responder group (36.4% vs 12.5%, p = 0.171), and non-responders showed a trend toward moderate-to-severe MGFA classifications (MGFA ≥ 2b, 81.8% vs 45.8%, p = 0.069), although these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.